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Abstract
The purpose of this study was to assess the usefulness of HER2 levels in ultrasonographically guided fine-needle aspiration
biopsy (US-FNA) aspirates of axillary lymph nodes (ALNs) in the determination of lymph node metastasis or the
characterization of primary breast cancer, and to correlate the HER2 levels in US-FNA aspirates (FNA-HER2s) of metastatic
ALNs with the HER2 statuses of corresponding primary breast cancers. An institutional review board approved the study.
Between January and October 2010, 164 patients with 167 ALNs examined by US-FNA were included. FNA-HER2s of ALNs
were measured by chemiluminescence immunoassay, and they were correlated with cytologic/final diagnoses. Receiver
operating characteristics (ROC) curve analysis was performed to evaluate the diagnostic ability to differentiate benign and
metastatic ALNs. Additionally, FNA-HER2s of metastatic ALNs were correlated with HER2 status and other clinicopathologic
variables of the primary breast cancers. Among the 167 ALNs, 138 were metastatic and 29 were benign. The mean FNA-
HER2 (6.3 ng/ml) of metastatic ALNs was higher than that of benign ALNs. All 29 benign ALNs showed no measurable value
of FNA-HER2 (0.0 ng/ml). The area under the ROC curves of FNA-HER2 of ALNs was 0.679 for the diagnosis of ALN
metastasis. The FNA-HER2 statuses of 108 metastatic ALNs (79.4%) were concordant with the HER2 statuses of the
corresponding primary breast cancers. In a subgroup analysis of HER2-positive cancers with ALN metastasis, distant
metastasis was significantly associated with FNA-HER2-negativity of metastatic ALNs (P= 0.04). Although FNA-HER2 of ALNs
did not improve the diagnostic performance of FNA cytology in preoperative diagnosis of ALN metastasis of overall
patients, FNA-HER2-positive metastatic ALNs were significantly associated with HER2-positivity of primary breast cancers.
Additionally, FNA-HER2 analysis of ALN may help to develop more personalized treatment protocol for breast cancer
patients by determining the concordance or discordance of HER2 status between primary cancers and metastatic ALNs.
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Introduction
Preoperative evaluation of axillary lymph node (ALN) status is
important to predict prognosis and to decide treatment plans for
breast cancer patients [1–3]. Axillary ultrasound (US) and
adjunctive US-guided fine needle aspiration biopsy (US-FNA)
for ultrasonographically suspicious ALNs are widely used for
preoperative staging of ALN, because of their simplicity and high
specificity, ranging up to 100% [3–7]. Although sentinel lymph
node biopsy (SLNB) is a standard procedure of ALN evaluation in
patients with invasive breast cancer [8,9], patients who have
positive cytologic results on preoperative US-FNA directly
undergo axillary lymph node dissection (ALND) or neoadjuvant
chemotherapy (NAC). However, broad ranges for the sensitivities
(21 to 86%) and negative predictive values (65 to 90%) of axillary
US combined with US-FNA have been reported [3–7,10,11],
which means that axillary US combined with US-FNA may lead
to a substantial number of false-negative cases in certain
circumstances. Consequently, SLNB is performed to confirm
ALN status for patients who have invasive breast cancers and
negative or indeterminate results on axillary US combined with
US-FNA, even though SLNB is an invasive surgical procedure
with a risk of radiation exposure to the operating team, and has
associated costs and a prolonged operation time [11]. Therefore,
non-surgical accurate methods that can preoperatively determine
ALN status would be clinically beneficial to simplify the ALN
staging process and to reduce unnecessary SLNB. Given this
situation, several studies have focused on identifying tumor
markers to determine ALN metastasis using fine needle aspirates
of ALN. Carcinoembryonic antigen (CEA), breast cancer antigen
15-3 (CA 15-3), and cytokeratin fragment 21-1 (CYFRA21-1) have
been proposed to be tumor markers which may be helpful for
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preoperative diagnosis of ALN metastasis in breast cancer patients
[12,13].
Metastatic cells obtained though needle-aspiration from axillary
lymph nodes can reveal characteristics with phenotypes of breast
cancer. One representative subtype of breast cancer is human
epidermal growth factor receptor 2 (HER2) type. HER2 is an
oncogene located on chromosome 17q21 and encodes a trans-
membrane glycoprotein with tyrosine kinase activity involved in
regulation of cell growth [14]. Amplification or overexpression of
the HER2 gene is identified in 15–30% of breast cancers and is
associated with more aggressive disease and poor prognosis [15].
The HER2 receptor can be a target for trastuzumab, which has
proven to be an effective treatment for HER2-positive breast
cancer [16]. Therefore, HER2 status evaluation is vital in the
pretreatment planning of therapeutic strategies. Immunohisto-
chemical (IHC) and fluorescence in situ hybridization (FISH)
analyses using formalin-fixed, paraffin-embedded tissue samples
are the most widely used methods for measuring HER2. However,
in some cases of metastatic or recurrent disease, only fine needle
aspiration biopsy (FNA) specimens might be available. In these
circumstances, it would be helpful to be able to identify HER2
status using FNA specimens.
The HER2 receptor consists of a cytoplasmic domain with
tyrosine kinase activity, a transmembrane domain, and an
extracellular domain (ECD). The ECD of the HER2 receptor
can be cleaved and released from the surface of breast cancer cells,
and can be detected by enzyme-linked immunosorbent assay
(ELISA) [17]. Using this method on serum samples, many
researchers have reported that higher serum HER2 concentrations
are associated with decreased treatment response and poor
prognosis [18–20]. Therefore, we hypothesized that it might be
possible to determine the HER2 status of FNA specimens from
ALNs via ELISA, and that this might have clinical utility in breast
cancer treatment.
The purpose of this study was to assess the usefulness of HER2
level measurement of US-FNA specimens (FNA-HER2) from
ALNs in the determination of lymph node metastasis or
characterization of primary breast cancer, and to compare the
HER2 status of metastatic ALNs based on FNA-HER2 with that
of primary breast cancer tissue.
Methods
Study population
This study was approved by the institutional review board of
Severance Hospital, Yonsei University College of Medicine, and
written informed consent was obtained from all patients. Between
January and October 2010, 167 women with invasive breast
cancers underwent US-FNA of 170 ALNs at our institution.
Among these, three patients who had previous mastectomies due
to malignancy were excluded. Ultimately, 164 patients with 167
ALNs examined by US-FNA were included in this study. One
patient had bilateral cancer and underwent US-FNA of bilateral
ALNs, and two patients underwent US-FNA of ipsilateral and
contralateral ALNs.
US and US-FNA of axillary lymph nodes
Preoperative axillary US was performed by seven breast
radiologists with various degrees of experience (2 to 13 years).
US equipment included Phillips ATL HDI, iU22 (Phillips-
Advanced Technology Laboratories, Bothell, WA, USA) machines
equipped with high-frequency linear transducers (5 to 12 MHz).
Bilateral axillary areas were scanned in an orthogonal direction
along the axillary artery from the lower axilla to the junction of the
axilla and upper arm. The following US features were used to
identify metastatic ALNs: loss of fatty hilum, cortical thickening
(.3 mm), irregular or round shape, markedly hypoechoic cortex,
or increased peripheral blood flow on Doppler US [13,21,22].
ALNs were considered suspicious when one or more suspicious US
features were detected, and US-FNA was recommended for all
suspected metastatic ALNs.
US-FNA was performed with a 23-gauge needle attached to a 2-
ml disposable syringe using freehand technique. Each lymph node
was aspirated at least twice. Immediately after aspiration, samples
were expelled onto glass slides and fixed in 95% alcohol for
Papanicolaou staining. The remnants in the needle and syringe
were rinsed with 1 ml of normal saline, and then the washout was
made. Each washout was centrifuged at 1,200 revolutions per
minute for 5 min at 4uC. The supernatants were carefully
collected for HER2 assays.
FNA-HER2 analysis
HER2 levels in FNA specimens (FNA-HER2) of ALNs were
measured by chemiluminescence immunoassay (ADIVIA Centaur
System, Siemens, Tarrytown, NY, USA), which is a two-site
sandwich immunoassay. Reagents contained two monoclonal
antibodies specific for unique epitopes on the extracellular domain
of the HER2 receptor.
Pathologic analysis
The cytologic results of FNA specimens were interpreted by five
cytopathologists with 1 to 15 years of experience, and were divided
into two categories. Reports of metastasis from breast cancer or
atypical cells were considered positive. Reports of reactive
hyperplasia or specific benign diagnoses (e.g. tuberculosis) were
considered negative. Reports of insufficient material were consid-
ered negative, because a patient with insufficient material on
cytologic report should undergo SLNB just like a patient with
negative cytologic results [4,13,23].
All 165 primary breast cancers were confirmed by preoperative
core needle biopsy. Among the 164 patients, 144 patients (87.8%)
had breast surgery and subsequent SLNB or axillary lymph node
dissection: unilateral breast surgery and ipsilateral SLNB/ALND
(n= 143), or unilateral breast surgery and bilateral ALND due to
contralateral ALN metastasis (n = 1). Among these patients, 102
received NAC before surgery. Twenty patients (12.2%) had not
been operated on due to presence of distant metastasis. Among
these, one patient had bilateral breast cancer and bilateral
metastatic ALNs, and one patient had unilateral breast cancer
and bilateral metastatic ALNs. For primary breast cancers, final
histopathologic results of surgical or core needle biopsy specimens
were used as reference standards. For ALNs, surgical histopath-
ologic results (n = 145) or the combination of cytologic results and
clinical evidence during follow-up (n= 22) were used as reference
standards. Among the ALNs confirmed by surgery, the aspirated
ALNs were correlated by the location seen at surgery.
IHC staining for HER2, estrogen receptor (ER), progesterone
receptor (PR), androgen receptor (AR), and Ki-67 were performed
on tissue blocks. Briefly, 5-mm sections were obtained with a
microtome, transferred onto adhesive slides, and dried at 62uC for
30 minutes. After incubation with primary antibodies against
HER2 (polyclonal, 1:1, 500; DAKO, Glostrup, Denmark), ER
(clone SP1, 1:100; Thermo Scientific, Fremont, CA, USA), PR
(clone PgR, 1:50; DAKO), AR (clone AR441, 1:50; DAKO), or
Ki-67 (clone MIB-1, 1:150; DAKO), immunodetection was
performed with biotinylated anti-mouse immunoglobulin, followed
by peroxidase-labeled streptavidin using a labeled streptavidin
biotin kit with 3,39-diaminobenzidine chromogen as substrate.
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Slides were counterstained with Harris hematoxylin. HER2
staining was scored as 0 to 3+, according to the guidelines of the
American Society of Clinical Oncology/College of American
Pathologists [24]. Cases scored as 3+ were counted as HER2-
positive, whereas cases scored as 0 to 1+ were counted as negative.
Borderline cases (2+) required further investigation using FISH to
measure gene amplification. In FISH analysis, a HER2 gene/
chromosome 17 (HER2/Chr17) ratio of higher than 2.2 was
considered HER2-positive. ER- and PR-positivity were defined as
higher than 10 fmol/mg cytosolic protein or as 10% or higher
nuclear IHC staining. AR positivity was defined as.10% tumor or
stromal cell positive staining. IHC staining for Ki-67 was scored by
counting the number of positively stained nuclei, and expressed as
a percentage of total tumor cells.
Data and statistical analysis
Clinicopathologic data were collected through review of
medical records. Clinicopathologic variables included size of
aspirated ALNs, tumor size of primary breast cancer, status of
HER2, ER, PR, AR, and Ki-67 expression in primary breast
cancer, and presence of distant metastasis at the time of diagnosis.
Size of aspirated ALNs was measured as the maximum diameter
on either transverse or longitudinal scan of preoperative US.
Tumor size of primary breast cancers was based on patients’ final
pathologic reports (113 patients who underwent operation without
NAC or preoperative US features obtained before treatment (31
patients who underwent operation after NAC and 20 patients who
had not been operated on due to distant metastasis). Information
on expression status of HER2, ER, PR, AR and Ki-67 were based
on patients’ final pathologic reports. For statistical analysis,
primary breast cancers were grouped by Ki-67 index (low,
,14% or high, $14%) and FISH HER2/Chr17 ratio (low, 2.2–
4.0 or high, .4.0).
FNA-HER2s of ALNs were compared according to cytologic/
final diagnosis using Student’s t-test. Receiver operating charac-
teristics (ROC) curve analysis was performed to evaluate the
diagnostic ability to differentiate benign from metastatic ALNs.
The optimal cut-off value was chosen to maximize the sum of
sensitivity and specificity. In addition, FNA-HER2s of metastatic
ALNs were compared with respect to clinicopathologic variables
using Student’s t-test and ANOVA. The FNA-HER2 statuses of
ALNs were divided into two arbitrary categories (negative or
positive) according to the FNA-HER2 cut-off value based on ROC
analysis. A chi-square test was used for comparison of the FNA-
HER2 status of metastatic ALNs to the HER2 status of the
corresponding primary breast cancer tissue. Statistical analysis was
performed with SAS for Windows, v. 9.0 (SAS Institute, Cary,
NC, USA). P values less than 0.05 were considered significant.
Results
Clinicopathologic patient characteristics
The mean age of the patients was 47.8 years (range, 27–76
years). The mean tumor size of primary breast cancers was
30.2 mm, and the most common histologic type was invasive
ductal carcinoma. Status of HER2, ER, PR, AR, and Ki-67
expression for primary breast cancer, and the presence of distant
metastasis at the time of diagnosis are presented in Table 1. Of the
165 invasive breast cancers, 59 were HER2-positive (35.8%).
Lymph node metastasis was observed in 138 aspirated ALNs from
136 cancers (82.4%). Distant metastasis was observed in 23
cancers (14.0%) from 21 patients, and the metastatic sites consisted
of lung, bone, liver, neck node, and brain, in order of frequency.
Diagnostic performance of FNA-HER2 in prediction of
ALN metastasis
Of the 167 ALNs, 138 (82.6%) were metastatic and 29 (17.4%)
were benign according to reference standards. The 138 metastatic
nodes were confirmed by surgery (n = 116) or with both clinical
evidence and cytologic results (n = 22), due to the presence of
distant metastasis. The cytology results from US-FNA of ALNs in
final metastatic nodes were: metastatic in 125 (74.9%), and benign
in 13 nodes (11 benign and 2 insufficient). All 29 of the finally
benign nodes had benign cytologic results (27 benign and 2
insufficient material for diagnosis). All 13 of the metastatic ALNs
yielding negative cytologic results had negative results (0.00 ng/
mL) by FNA-HER2 analysis. The 29 benign ALNs also had no
measurable value of HER2. Of the 138 metastatic ALNs, 52 ALNs
(37.7%) had positive results (.0.00 ng/mL) by FNA-HER2
analysis. The mean FNA-HER2 (mean 6.31, range 0–154.60) of
the metastatic ALNs was higher than that of the benign ALNs,
although a substantial number of metastatic ALNs (86/138) had
negative results by FNA-HER2 analysis (Figure 1). The area
under the ROC curves (Az value) of FNA-HER2s of ALNs was
0.679 for the diagnosis of ALN metastasis, and the optimal cut-off
level was 0.00 ng/mL (sensitivity 37.7%, specificity 100%), while
the Az value of US-FNA cytology was 0.953 (sensitivity 90.6%,
specificity 100%). Addition of FNA-HER2 to the US-FNA
cytologic results did not improve the Az value for the prediction
of ALN metastasis. In subgroup ROC analysis of 59 patients with
HER2-positive primary breast cancers, the Az value of FNA-
HER2 was 0.865, and the optimal cut-off level was 0.00 ng/mL
(sensitivity 73.1%, specificity 100%) for the diagnosis of ALN
metastasis. In this subgroup, the Az value of US-FNA cytology
(0.981) was also significantly higher than that of FNA-HER2
(P=0.04).
Comparison of FNA-HER2 status of metastatic ALNs and
HER2 status of their corresponding primary breast
cancers
Table 2 shows the concordance and discordance between the
FNA-HER2 statuses of metastatic ALNs and the HER2 statuses of
the corresponding primary breast cancer tissues in 133 patients
with 136 metastatic ALNs. Two metastatic ALNs with insufficient
cytologic results were excluded from this analysis. The FNA-
HER2 status of ALNs was based on the level of FNA-HER2, and
the HER2 status of primary breast cancer tissue was based on a
combination of IHC and FISH results. The FNA-HER2 statuses
of 108 metastatic ALNs (79.4%) were concordant with the HER2
statuses of their corresponding primary breast cancers. For the
concordant metastatic ALNs, the mean FNA-HER2 was 23.1 ng/
ml (range 0.2–154.6). There were also 28 metastatic ALNs with
discordance (20.6%) between the FNA-HER2 status of the ALN
and the HER2 status of the corresponding primary breast cancer
tissue. There were 14 metastatic ALNs which were FNA-HER2-
positive whose corresponding primary breast cancers were HER2-
negative, and the mean FNA-HER2 of these ALNs was 3.0 ng/ml
(range 0.1–20.3 ng/ml). Of those, two metastatic ALNs had
higher FNA-HER2s (range 6.5–20.3 ng/ml) than did the remain-
der (range 0.1–4.9 ng/ml). Of these two HER2-negative primary
cancers whose corresponding metastatic ALNs had the highest
FNA-HER2s, one had an IHC score of 1+ but high gene
amplification by FISH, and the other had an IHC score of 1+
before NAC, but an IHC score of 3+ after NAC. There were 14
other metastatic ALNs which were FNA-HER2-negative, but
whose corresponding primary breast cancers were HER2-positive.
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FNA-HER2 of metastatic ALNs according to
clinicopathologic features
As shown in Table 3, the mean FNA-HER2 of metastatic ALNs
was found to be significantly associated with HER2-positivity, high
HER2 IHC grade, and high HER2 amplification by FISH of the
corresponding primary breast cancers. Additionally, metastatic
ALNs from primary ER-negative and PR-negative breast cancers
had significantly higher FNA-HER2s than did those that were not
ER- and PR-negative. However, there were no significant
differences in the mean FNA-HER2s of metastatic ALNs
according to metastatic ALN size or the Ki-67 or AR status of
the corresponding primary breast cancers.
In addition, we analyzed the clinicopathologic features of 52
HER2-positive primary breast cancers according to the FNA-
HER2 status of their metastatic ALNs (Table 4). In this subgroup
analysis of HER2-positive cancers with ALN metastasis, distant
metastasis was more frequently seen in the discordant group
(HER2-positive primary cancer but FNA-HER2-negative meta-
static ALN) than in the concordant group, with statistical
significance (P=0.04). The mean size of metastatic ALNs and
primary cancers, HER2 amplification by FISH, and the HER2
IHC grade of primary breast cancers were not significantly
different between the two groups.
Table 1. Characteristics of 165 invasive breast cancers in 164 patients examined by preoperative axillary US.
Characteristics Number of primary breast cancers (%)
Histologic type Invasive ductal carcinoma 148 (89.8)
Invasive papillary carcinoma 5 (3.0)
Invasive lobular carcinoma 4 (2.4)
Mucinous carcinoma 3 (1.8)
Metaplastic carcinoma 3 (1.8)
Medullary carcinoma 1 (0.6)
Neuroendocrine carcinoma 1 (0.6)
HER2 Negative 106 (64.2)
Positive 59 (35.8)
ER Negative 69 (41.8)
Positive 96 (58.8)
PR Negative 94 (57.0)
Positive 71 (43.0)
Ki-67 Low 51 (30.9)
High 84 (50.9)
N/A 30 (18.2)
AR Negative 51 (30.9)
Positive 84 (50.9)
N/A 30 (18.2)
Lymph node metastasis Negative 29 (17.6)
Positive 136 (82.4)
Distant metastasis Negative 142 (86.0)
Positive 23 (14.0)
N/A: not available.
doi:10.1371/journal.pone.0113065.t001
Figure 1. FNA-HER2 of 167 axillary lymph nodes in 165 invasive breast cancers.
doi:10.1371/journal.pone.0113065.g001
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Discussion
US-FNA is a commonly used diagnostic method for preoper-
ative staging of ALNs. However, a substantial number of false
negative results can occur in US-FNA cytology [10], and therefore
several markers in US-FNA specimens, such as CEA, CA15-3, and
CYFRA 21-1, have been investigated in previous studies to
improve the diagnostic performance of preoperative US-FNA
cytology [12,13]. In the current study, we evaluated whether FNA-
HER2 of ALN can improve the diagnostic performance of US-
FNA cytology in preoperative diagnosis of ALN metastasis. Our
results showed that FNA-HER2 did not improve the sensitivity of
US-FNA cytology, because a substantial number of metastatic
ALNs (62.3%), including metastatic ALNs with false negative
cytologic results, gave negative results on FNA-HER2. This may
be a predictable result, because HER2 expression is seen in some
portion of overall breast cancers. Therefore, FNA-HER2 may not
be useful in preoperative ALN staging for overall breast cancer
patients. However, all ALNs with positive FNA-HER2 were
metastatic; moreover, a higher FNA-HER2 in our metastatic
ALNs was significantly associated with HER2-positivity of
Table 2. Comparison of FNA-HER2 status of 136 metastatic ALNs with HER2 status of the corresponding primary breast cancer
tissue.
FNA-HER2 status of ALNs
Positive Negative P
HER2 status of primary breast cancer Positive (n = 52) 38 (73.1) 14 (26.9) ,0.01
Negative (n = 84) 14 (16.7) 70 (83.3)
Non-numeric data are presented as number of lymph nodes (percentage).
doi:10.1371/journal.pone.0113065.t002
Table 3. Associations between FNA-HER2 of 136 metastatic ALNs and clinicopathologic features of their primary breast cancers.
FNA-HER2 level (ng/ml)
Characteristics Number of axillary lymph nodes Mean (SD) P
Metastatic ALN size #10 mm 30 3.77 (12.89) 0.16
.10 and #20 mm 83 5.69 (17.38)
.20 23 14.63 (21.88)
Primary cancer sizea #20 mm 21 1.68 (3.93) 0.36
.20 and #50 mm 88 7.78 (23.59)
.50 mm 15 2.47 (9.52)
HER2 IHC score 0 or 1 44 0.61 (3.15) ,0.01
2+ 58 4.19 (16.32)
3+ 33 19.71 (35.95)
HER2 amplification by FISHa,b None 68 0.31 (1.09) ,0.01
Low 18 26.77 (45.52)
High 29 12.67 (24.51)
HER2 status (IHC+FISH) Negative 84 0.50 (2.40) ,0.01
Positive 52 16.91 (32.98)
ER Negative 57 13.03 (30.50) ,0.01
Positive 79 2.26 (10.53)
PR Negative 80 10.01 (26.45) 0.04
Positive 56 2.15 (11.52)
Ki-67a Negative 45 4.48 (11.73) 0.29
Positive 62 9.55 (30.01)
ARa Negative 43 7.52 (22.10) 0.97
Positive 64 7.35 (25.56)
Distant metastasis Negative 113 6.24 (20.28) 0.53
Positive 23 9.40 (28.85)
IHC: immunohistochemistry.
aCases with no available results for each characteristic were excluded from data analysis: two cases for primary cancer size, 22 cases for HER2 FISH, and 29 cases for AR
and KI-67 status.
bHER2 FISH test were performed for 58 cases with borderline (2+) IHC results and for 57 cases on the recommendation of either the physician or the pathologist.
doi:10.1371/journal.pone.0113065.t003
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corresponding primary breast cancers in this study (P,0.001).
Accordingly, the Az value of FNA-HER2 was higher in a
subgroup analysis of HER2-positive breast cancers (0.865), than
for overall patients (0.679) in this study. Nevertheless, the Az value
of FNA cytology (0.981) was still higher than that of FNA-HER2
in this subgroup, and all 13 metastatic ALNs yielding negative
cytologic results had negative FNA-HER2 (0.00 ng/mL). Consid-
ering these findings, FNA-HER2 of ALNs may not improve the
diagnostic performance of FNA cytology in preoperative diagnosis
of ALN metastasis in breast cancer patients.
Since the clinical application of the humanized anti-HER2
antibody, trastuzumab, as a clinical anticancer agent for HER2-
positive breast cancer, selection of trastuzumab treatment has been
based on the HER2 status of primary tumors [16,25,26]. This is
due to initial studies which suggested that the HER2-status of
breast cancer is stable through the course of the disease [27,28].
However, some researchers have reported that the HER2 status of
primary tumors can be discordant with the HER2 status of
metastatic lymph nodes [29–31]. This HER2 status discrepancy
between primary breast cancer and metastatic lymph node
suggests that patients who have HER2-negative primary cancers
but HER2-positive metastatic lymph nodes may miss the
opportunity for successful treatment with tratsuzumab combina-
tion therapy. Nonetheless, the majority of breast cancer patients
have concordant HER2 statuses between their primary cancer and
metastatic ALN [29–31]. It would be clinically inefficient to
evaluate the HER2 status of both the primary cancer and
metastatic ALN using IHC/FISH analysis, which requires the
time-consuming process of slide preparation, and is mainly
applicable to tissue samples obtained by surgical or core needle
biopsy [32]. Accordingly, we hoped that FNA-HER2 of ALN
might be a clinically useful method for preoperative detection of
metastatic ALNs with HER2 discrepancy, given that US-FNA is a
widely used method for the preoperative diagnosis of ALN
metastasis. In this study, the majority (79.4%, 108/136) of the
FNA-HER2 statuses of metastatic ALNs were concordant with the
HER2 statuses of their corresponding primary cancers as
determined by IHC/FISH. On the other hand, discordant
FNA-HER2 statuses of metastatic ALNs were found in 20.6%
(28/136) of metastatic ALNs, which is consistent with values
(16–34%) reported in previous studies that used IHC/FISH
analysis for the evaluation of the HER2 statuses of primary and
metastatic tumors [29–31]. There are several hypotheses that may
account for the discordance between the FNA-HER2 of metastatic
ALNs and the IHC/FISH HER2 status of primary breast cancers.
First, it may be attributed to the genetic mutations in HER2 that
can occur during tumor progression [33]. On the other hand,
there can be small neoplastic clones that not only may have a
different HER2 status from the majority of the primary cancer
cells, but also may have enhanced potential to metastasize, leading
to metastases of clones with discordant HER2 genes from the
primary tumor [34,35]. Our one discordant case, which was
designated as HER2-negative primary breast cancer with FNA-
HER2 positive metastatic ALN before NAC, but as HER2-
positive breast cancer after NAC, may support this hypothesis.
However, most of our discordant cases underwent NAC and
exhibited pathologic complete response in surgical specimens, and
thus we could not compare the pre- and post-treatment HER2
statuses of these primary cancers. Consequently, it may be inferred
that the FNA-HER2 of metastatic ALNs may identify metastatic
ALNs exhibiting HER2 discrepancy with the primary tumor. In
addition, FNA-HER2 analysis of ALNs may have a potential role
in decision-making with respect to the use of trastuzumab
treatment and the development of targeted therapy for breast
cancer patients.
We evaluated the association between clinicopathologic features
of primary breast cancers and the FNA-HER2 of their metastatic
ALNs. FNA-HER2 levels of metastatic ALNs were positively
associated with HER2-positivity, high HER2 IHC score, and high
HER2 amplification by FISH, of primary breast cancers. We also
observed that metastatic ALNs of ER/PR-negative breast cancers
showed higher FNA-HER2s than those that were not ER/PR-
negative. However, this finding may be a consequence of the fact
that the majority of our ER/PR-negative breast cancers with ALN
metastasis were HER2-positive. In a subgroup analysis of HER2-
positive breast cancers with ALN metastasis, we found that distant
metastasis was more frequently seen in the FNA-HER2 negative
group than in the FNA-HER2 positive group, which was
statistically significant. A recent study has shown that breast
cancer patients with HER2 discordance between primary and
Table 4. Analysis of clinicopathologic features of 52 HER2-positive primary breast cancers according to FNA-HER2 status of their
metastatic ALNs.
FNA-HER2 status
Characteristics Positive (concordant) Negative (discordant) P
Number of cancers 38 14
Mean size of metastatic ALNs (mm) 15.268.5 13.266.3 0.44
Mean size of primary cancers (mm)* 29.5615.1 26.8613.4 0.61
HER2 status (IHC+FISH)* 0.59
IHC 2+ and low HER2 amplification by FISH 7 (18.4) 1 (7.2)
IHC 2+ and high HER2 amplification by FISH 8 (21.1) 3 (21.4)
IHC 3+ 23 (60.5) 10 (71.4)
Distant metastasis 0.04
Negative 34 (89.5) 9 (64.3)
Positive 4 (10.5) 5 (35.7)
Numeric data are presented as mean 6 SD (standard deviation).
Non-numeric data are presented as number of cancers (percentage).
*Cases with no available results for each characteristic were excluded from data analysis: two cases for primary cancer size, and 5 cases for HER2 FISH.
doi:10.1371/journal.pone.0113065.t004
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metastatic tumors had worse overall survival and post-recurrence
survival compared to the concordant group [36]. Considering this
with our own results, it may be inferred that patients with HER2-
positive breast cancer may have poor prognoses in the case of
HER2-discordant ALN metastasis, relative to those with HER2-
concordant ALN metastasis. This may be explained by intratu-
moral heterogeneity in the HER2 expression of cancer cells, which
was significantly associated with decreased disease-free survival of
HER2-positive breast cancer patients in a recent study [37].
Therefore, further studies with larger numbers of patients may
help confirm the relationship between HER2 discrepancy between
primary cancer and metastatic ALN, and poor prognosis.
This study has several limitations. First, our sample size was
relatively small. Second, we measured FNA-HER2 of ALNs by
ELISA targeting the ECD of the HER2 receptor. Secretion of the
ECD of the HER2 receptor may be affected by tumor load/size,
or by activity of tissue metalloproteinase [38]. Therefore, a small
number of cancer cells or a difference in the activity of tissue
metalloproteinase in metastatic ALNs may result in variability in
our FNA-HER2 measurements, which could lead to a FNA-
HER2 discordance with the HER2 status of the corresponding
primary breast cancer. Therefore, further studies with larger
numbers of patients are necessary for validation of our FNA-
HER2 analysis. Third, we only included ALNs with suspicious US
features, because US-FNA was not routinely recommended for
ALNs without suspicious features at our institution. Finally, we did
not analyze the cost effectiveness of FNA-HER2 analysis of ALN.
Conclusions
FNA-HER2 positive metastatic ALNs were significantly associ-
ated with HER2-positivity of primary breast cancers, although
FNA-HER2 of ALNs did not improve the diagnostic performance
of FNA cytology with respect to preoperative diagnosis of ALN
metastasis of overall patients. In addition, FNA-HER2 analysis of
ALN may help to develop more personalized treatment protocols
for breast cancer patients by determining the concordance or
discordance of HER2 status between primary cancers and
metastatic ALNs.
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